Validation of the French translation-adaptation of the impact of cancer questionnaire version 2 (IOCv2) in a breast cancer survivor population

Health and Quality of Life Outcomes

Jean-Benoit Hardouin¹  Neil K. Aaronson³  Anne Brédart⁴  Alejandra Cano⁵  Sarah Dauchy⁵  Myriam Blanchin² 

[1] Unit of Methodology and Biostatistics – University Hospital of Nantes, Nantes, France;EA4275, Biostatistics, Pharmacoepidemiology and Subjective Measures in Health Sciences, University of Nantes, Nantes, France;Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands;Psycho-oncology Unit, Department of Supportive Care – DISSPO, Institut Curie and University Paris Descartes, Psychopathology and Health Process Laboratory LPPS EA 4057, Paris, France;Psycho-oncology Unit, Department of Supportive Care, Gustave Roussy, Villejuif, France

关键词: Psychosocial;    Psychometric properties;    Questionnaire;    Breast cancer;    Survivorship;    Cancer survivor;   

Others  :  1224738
DOI  :  10.1186/s12955-015-0301-x

 received in 2014-10-30, accepted in 2015-07-09,  发布年份 2015

【 摘 要 】

Background

The Impact of Cancer version 2 (IOCv2) was designed to assess the physical and psychosocial health experience of cancer survivors through its positive and negative impacts. Although the IOCv2 is available in English and Dutch, it has not yet been validated for use in French-speaking populations. The current study was undertaken to provide a comprehensive assessment of the reliability and validity of the French language version of the IOCv2 in a sample of breast cancer survivors.

Methods

An adapted French version of the IOCv2 as well as demographic and medical information were completed by 243 women to validate the factor structure divergent/divergent validities and reliability. Concurrent validity was assessed by correlating the IOCv2 scales with measures from the SF-12, PostTraumatic Growth Inventory and Fear of Cancer Recurrence Inventory.

Results

The French version of the IOCv2 supports the structure of the original version, with four positive impact dimensions and four negative impact dimensions. This result was suggested by the good fit of the confirmatory factor analysis and the adequate reliability revealed by Cronbach's alpha coefficients and other psychometric indices. The concurrent validity analysis revealed patterns of association between IOCv2 scale scores and other measures.

Unlike the original version, a structure with a Positive Impact domain consisting in the IOCv2 positive dimensions and a Negative Impact domain consisting in the negative ones has not been clearly evidenced in this study. The limited practical use of the conditional dimensions Employment Concerns and Relationship Concerns, whether the patient is partnered or not, did not make possible to provide evidence of validity and reliability of these dimensions as the subsets of sample to work with were not large enough. The scores of these conditional dimensions have to be used with full knowledge of the facts of this limitation of the study.

Conclusions

Integrating IOCv2 into studies will contribute to evaluate the psychosocial health experience of the growing population of cancer survivors, enabling better understanding of the multi-dimensional impact of cancer.

【 授权许可】

   
2015 Blanchin et al.

【 参考文献 】

• [1]Knobf MT. Psychosocial Responses in Breast Cancer Survivors. Semin Oncol Nur. 2007; 23(1):71-83.
• [2]Knobf MT. Clinical Update: Psychosocial Responses in Breast Cancer Survivors. Semin Oncol Nurs. 2011; 27(3):e1-e14.
• [3]Denlinger CS, Barsevick AM. The Challenges of Colorectal Cancer Survivorship. J Natl Compr Cancer Netw. 2009; 7(8):883-894.
• [4]Ewertz M, Jensen AB. Late effects of breast cancer treatment and potentials for rehabilitation. Acta Oncol. 2011; 50(2):187-193.
• [5]Montazeri A. Health-related quality of life in breast cancer patients: a bibliographic review of the literature from 1974 to 2007. J Exp Clin Cancer Res. 2008; 27:32. BioMed Central Full Text
• [6]Rowland KB, Rodriguez JL, Patterson JR, Trivers KF. A literature review of the social and psychological needs of ovarian cancer survivors. Psycho-Oncology. 2013; 22(11):2408-2418.
• [7]Jim HS, Jacobsen PB. Posttraumatic stress and posttraumatic growth in cancer survivorship: a review. Cancer J. 2008; 14(6):414-419.
• [8]Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A et al.. The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology. J Natl Cancer Inst. 1993; 85(5):365-376.
• [9]Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J. The Functional Assessment of Cancer Therapy Scale: Development and Validation of the General Measure. J Clin Oncol. 1993; 11(3):570-579.
• [10]Avis NE, Smith KW, McGraw S, Smith RG, Petronis VM, Carver CS. Assessing quality of life in adult cancer survivors (QLACS). Qual Life Res. 2005; 14(4):1007-1023.
• [11]Ferrell BR, Dow KH, Grant M. Measurement of the quality of life in cancer survivors. Qual Life Res. 1995; 4(6):523-531.
• [12]Zebrack BJ, Ganz PA, Bernaards CA, Petersen L, Abraham L. Assessing the impact of cancer: development of a new instrument for long-term survivors. Psycho-Oncology. 2006; 15(5):407-421.
• [13]Crespi CM, Ganz PA, Petersen L, Castillo A, Caan B. Refinement and Psychometric Evaluation of the Impact of Cancer Scale. J Natl Cancer Inst. 2008; 100(21):1530-1541.
• [14]Breaden K. Cancer and beyond: the question of survivorship. J Adv Nurs. 1997; 26(5):978-984.
• [15]Dewolf L, Koller M, Velikova G, Johnson C, Scott N, Bottomley A. EORTC Quality of Life Group Translation Procedure. 3rd ed. EORTC Quality of Life Group, Brussels; 2009.
• [16]Ware J, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: Construction of Scales and Preliminary Tests of Reliability and Validity. Med Care. 1996; 34(3):220-233.
• [17]Gandek B, Ware JE, Aaronson NK, Apolone G, Bjorner JB, Brazier JE et al.. Cross-Validation of Item Selection and Scoring for the SF-12 Health Survey in Nine Countries: Results from the IQOLA Project. J Clin Epidemiol. 1998; 51(11):1171-1178.
• [18]Tedeschi RG, Calhoun LG. The Posttraumatic Growth Inventory: Measuring the positive legacy of trauma. J Trauma Stress. 1996; 9(3):455-471.
• [19]Simard S, Savard J. Fear of Cancer Recurrence Inventory: development and initial validation of a multidimensional measure of fear of cancer recurrence. Support Care Cancer. 2009; 17(3):241-251.
• [20]Schermelleh-Engel K, Moosbrugger H, Müller H. Evaluating the fit of structural equation models: Test of significance and descriptive goodness-of-fit measures. Methods Psychol Res- Online. 2003; 8(2):23-74.
• [21]Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika. 1951; 16(3):297-334.
• [22]Ferguson GA. On the theory of test discrimination. Psychometrika. 1949; 14(1):61-68.
• [23]Hankins M. Questionnaire discrimination: (re)-introducing coefficient delta. BMC Med Res Methodol. 2007; 7:19. BioMed Central Full Text
• [24]Sijtsma K, Molenaar IW. Introduction to Nonparametric Item Response Theory. Sage, Thousand Oaks, CA; 2002.
• [25]Oerlemans S, Smith SK, Crespi CM, Zimmerman S, van de Poll-Franse LV, Ganz PA. Assessing the impact of cancer among Dutch non-Hodgkin lymphoma survivors compared with their American counterparts: a cross-national study. Psycho-Oncology. 2013; 22(6):1258-1265.
• [26]Crespi CM, Smith SK, Petersen L, Zimmerman S, Ganz PA. Measuring the impact of cancer: a comparison of non-Hodgkin lymphoma and breast cancer survivors. J Cancer Surviv. 2010; 4(1):45-58.
• [27]Smith SK, Crespi CM, Petersen L, Zimmerman S, Ganz PA. The Impact of Cancer and Quality of Life for Post-Treatment Non-Hodgkin Lymphoma Survivors. Psycho-Oncology. 2010; 19(12):1259-1267.
• [28]Kieffer JM, Djajadiningrat RS, van Muilekom EA, Graafland NM, Horenblas S, Aaronson NK. Quality of Life in Patients Treated for Penile Cancer. J Urol. 2014; 192(4):1105-10.